SNNVF (Sunniva) EBITDA Margin %: -101.70% (As of Sep. 2019)


What is Sunniva EBITDA Margin %?

Sunniva SNNVF EBITDA Margin % is -101.70% as of Sep. 2019.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sunniva's EBITDA for the three months ended in Sep. 2019 was $-4.12 Mil. Sunniva's Revenue for the three months ended in Sep. 2019 was $4.05 Mil. Therefore, Sunniva's EBITDA margin for the quarter that ended in Sep. 2019 was -101.70%.

Sunniva  (OTCPK:SNNVF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Sunniva EBITDA Margin % Related Terms

Sunniva EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Sunniva's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunniva EBITDA Margin % Chart

Sunniva Annual Data
Trend Dec16 Dec17 Dec18
EBITDA Margin %
-18,296.43 -104.46 -135.55

Sunniva Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -420.95 -78.20 -14.96 -235.48 -101.70

SNNVF vs ZTS: EBITDA Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sunniva's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sunniva EBITDA Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sunniva's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Sunniva's EBITDA Margin % falls into.


Sunniva EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Sunniva's EBITDA Margin % for the fiscal year that ended in Dec. 2018 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2018 )/Revenue (A: Dec. 2018 )
=-18.956/13.984
=-135.55 %

Sunniva's EBITDA Margin % for the quarter that ended in Sep. 2019 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2019 )/Revenue (Q: Sep. 2019 )
=-4.118/4.049
=-101.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -101.70% mean?
Sunniva (SNNVF) has a EBITDA Margin % of -101.70% as of Sep. 2019. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sunniva and its competitors.
Is Sunniva's EBITDA Margin % too high?
Sunniva's current EBITDA Margin % is -101.70%.
How does Sunniva's EBITDA Margin % compare to ZTS?
Sunniva's EBITDA Margin % of -101.70% can be compared against companies in the Drug Manufacturers industry. The industry median EBITDA Margin % is 12.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sunniva and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunniva's current EBITDA Margin % is -101.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunniva stock overvalued right now?
Sunniva (SNNVF) has a current EBITDA Margin % of -101.70%. The current EBITDA Margin % is -101.70%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sunniva (SNNVF), the current EBITDA Margin % is -101.70% as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sunniva Business Description

Address 200 Burrard Street, 1200 Waterfront Centre, P.O Box 48600, Vancouver, BC, CAN, V7X 1T2
Sunniva Inc is vertically integrated medical cannabis company committed to delivering safe, low-cost, high-quality products and services at scale. The company is focused on the cultivation, production and distribution of therapeutic solutions targeting two of the medical cannabis markets in the world: Canada and California.